Menu

California Institutes to Merge

The Scripps Research Institute will join forces with the California Institute for Biomedical Research.

Oct 25, 2016
Jef Akst

FLICKR, HÅKAN DAHLSTRÖMChemist Peter Schultz is bringing together his two nonprofit institutions—the Scripps Research Institute (TSRI) and the California Institute for Biomedical Research (Calibr)—merging them into a new biomedical research entity, according to a statement issued last week (October 20). The hope is that basic research conducted at TSRI can be fed into Calibr for preclinical and clinical development.

“The affiliation between TSRI and Calibr is the first of its kind,” Schultz, who is president of both organizations, said in the press release. “Unlike other research institutes and universities that have sought to establish translational capabilities within academic centers, we aren’t building from scratch—rather, we are integrating the strengths of two proven nonprofit organizations.”

The two institutions have collaborated since Calibr was launched in 2012, but the merge will allow them to share a board of directors as well as scientific and administrative resources, reducing overhead costs for both organizations. 

(Hat tip: Science)

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.